GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04171765
- Locations
- πΊπΈ
National Research Inst., Los Angeles, California, United States
πΊπΈSouth Denver Gastroenterology, Englewood, Colorado, United States
πΊπΈGastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT04092582
- Locations
- πΊπΈ
Florida Ctr-Allergy & Asthma, Miami, Florida, United States
π΅π±ALL-MED Specjalistyczna Opieka Medyczna, Wroclaw, Poland
πΊπΈKern Research, Bakersfield, California, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04045028
- Locations
- πΊπΈ
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States
πΊπΈClinical Research Alliance, Westbury, New York, United States
πΊπΈUniversity of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT03972709
- Locations
- πΊπΈ
Retina Consultants of Orange County, Fullerton, California, United States
πΊπΈAssociated Retinal Consultants PC, Royal Oak, Michigan, United States
πΊπΈSierra Eye Associates, Reno, Nevada, United States
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03961100
- Locations
- π¬π§
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03916744
- Locations
- π§πͺ
Clinique Sainte-Elisabeth; Oncologie, Namur, Belgium
πΊπΈUniversity of Colorado, Aurora, Colorado, United States
πͺπΈHM Sanchinarro ? CIOCC, Madrid, Spain
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03828747
- Locations
- πΊπΈ
Miami Jewish Health Systems, Miami, Florida, United States
πΊπΈPharmacology Research Institute, Los Alamitos, California, United States
πΊπΈCollier Neurologic Specialists, Naples, Florida, United States
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- Conditions
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT03815058
- Locations
- πΊπΈ
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUniversity of California San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
- Conditions
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03807739
- Locations
- πΊπΈ
Covance Research Unit - Dallas, Dallas, Texas, United States
πΊπΈCovance Research Unit - Daytona, Daytona Beach, Florida, United States
A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03796013
- Locations
- πΊπΈ
Covance Research Unit - Dallas, Dallas, Texas, United States